Russet -
"Are we overestimating the market for Pennsaid?"
That was your question, not mine. I was merely repeating it, as a representative question from "the market".
If you go back on this thread (I don't know if you're an investor, a short, or what) you will find graphs, with percentage sales projections, from other posters. All the info which you purport to "know" is there, in plain sight.
The questions about the UK have been answered a thousand times (differences in the market, differences in marketing, different rates of uptake). As DMX itself has said, we are now entering the stage where presciptions will be renewed; we can expect an upturn each year.
A search on this forum will answer most, if not all your questions.
The purpose of my post was to point out that the time is rapidly approaching when answers from posters will not suffice, logical and reasonable though they may be.
The time is approaching when results will have to speak.
As to your other points, a little bit of DD will find all your questions answered. "...I was here too listening".
Au contraire, mon ami, you appear not to have read any of the posts that have dealt with your questions in considerable detail.
"But if the drug can't make it in the UK in a short time,...why should anywhere else be any different? When does that patent run out?
Good news travels by airplane, bad news by mule train,...how long has that marketing experiment been going on in the UK anyway'
Do you have any idea what you're talking about? On what basis do you conclude that the drug "...can't make it in the UK"?
The uptake is slow; it is expected to be slow. Its slowness is understandable. We're not selling Viagra, here. Have you read any of the posts dealing with the differences between the UK and North America? Explaining how the UK medical community adopts new drugs?
Either you're too lazy to perform a little DD, or you're doing a little back-door bashing.
Regards,
Jim |
